Lung cancer
Conditions
Interventions
Control group:symptomatic treatment
Experimental Group:Yifei Lizhong Decoction+symptomatic treatment
Sponsors
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with Stage Ia–IIIa non-small cell lung cancer (NSCLC) by pathology and imaging who have undergone video-assisted thoracoscopic surgery (VATS) and are scheduled to receive medical treatment within 1–7 days after surgery; (2) No gender limitation aged =18 years and =80 years; (3) Eastern Cooperative Oncology Group (ECOG) performance status score =2 with an expected survival of =3 months; (4) Patients with the traditional Chinese medicine syndrome differentiation of lung-spleen qi deficiency; (5) Patients who understand the nature of this study and are willing to sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with known allergies to the main components of Yifei Lizhong Decoction; (2) Patients with postoperative air leakage exceeding 7 days; (3) Pregnant and breastfeeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of symptom threshold events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Trajectory of symptom burden;Clinical Syndromes of Lung Cancer in Traditional Chinese Medicine;Tumor markers;Exercise tolerance status;Microbial community changes;Inflammatory and immune status;Pulmonary complications; | — |
Countries
China
Contacts
Public ContactLing Xu
Department of Oncology I Yueyang Hospital of Integrated Traditional Chinese and Western Medicin
Outcome results
None listed